Amended: The article, posted on September 17, 2025, about Omeros Corp. (OMER) incorrectly mentioned the PDUFA date as September 25, 2025.
Omeros Corp. (OMER) is approaching a pivotal regulatory milestone as the FDA prepares to issue its decision on the Biologics License Application (BLA) for narsoplimab, the company's lead investigational therapy. The FDA has assigned a PDUFA target action date of December 26, 2025, for its review of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy/TA-TMA.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.